Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Cholangiocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Biliary Tract Cancer (321
)
Gallbladder Cancer (41
)
Biliary Tract Cancer (321
)
Gallbladder Cancer (41
)
›
Associations
(181)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
Cholangiocarcinoma
HER-2 positive
Cholangiocarcinoma
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 3 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 3d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 3 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 3 days - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 1wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week
futibatinib
Sensitive
:
A1
N Engl J Med - 1 week - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 1wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week
futibatinib
Sensitive
:
A1
N Engl J Med - 1 week - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 1 week (New C4)
palbociclib
Sensitive
:
C4
Onco Targets Ther - 1wk
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 1 week
palbociclib
Sensitive
:
C4
Onco Targets Ther - 1 week - (New C4)
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 1 week (New C4)
capmatinib
Sensitive
:
C4
The Oncologist - 1wk
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 1 week
capmatinib
Sensitive
:
C4
The Oncologist - 1 week - (New C4)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Cholangiocarcinoma
MDM2 amplification
Cholangiocarcinoma
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion
Cholangiocarcinoma
FGFR fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
infigratinib
Sensitive: B - Late Trials
infigratinib
Sensitive
:
B
infigratinib
Sensitive: B - Late Trials
infigratinib
Sensitive
:
B
HER-2 expression
Cholangiocarcinoma
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
TT-00420
Sensitive: B - Late Trials
TT-00420
Sensitive
:
B
TT-00420
Sensitive: B - Late Trials
TT-00420
Sensitive
:
B
RET fusion
Cholangiocarcinoma
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
BRCA2 mutation
Cholangiocarcinoma
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
BRCA1 mutation
Cholangiocarcinoma
BRCA1 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
FGFR3 mutation
Cholangiocarcinoma
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
KRAS G12C
Cholangiocarcinoma
KRAS G12C
Cholangiocarcinoma
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
NTRK2 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
NTRK1 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
MSI-H/dMMR
Cholangiocarcinoma
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
BRAF V600E
Cholangiocarcinoma
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
NTRK2 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
NTRK1 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
HER-2 overexpression
Cholangiocarcinoma
HER-2 overexpression
Cholangiocarcinoma
lapatinib
Sensitive: C1 - Off-label
lapatinib
Sensitive
:
C1
lapatinib
Sensitive: C1 - Off-label
lapatinib
Sensitive
:
C1
BRAF V600E
Cholangiocarcinoma
BRAF V600E
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
FGFR2 translocation
Cholangiocarcinoma
FGFR2 translocation
Cholangiocarcinoma
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive: C2 – Inclusion Criteria
infigratinib
Sensitive
:
C2
infigratinib
Sensitive: C2 – Inclusion Criteria
infigratinib
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
FGFR2 amplification
Cholangiocarcinoma
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login